Alibaba
BABA
Micron Technology
MU
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
US Stock MarketDetailed Quotes
SNGX Soligenix
- 2.3900
- -0.0700-2.85%
Close Feb 14 16:00 ET
- 2.2645
- -0.1255-5.25%
Post 20:01 ET
6.00MMarket Cap-0.37P/E (TTM)
2.4600High2.3100Low40.58KVolume2.4300Open2.4600Pre Close96.03KTurnover1.62%Turnover RatioLossP/E (Static)2.51MShares14.918452wk High1.01P/B6.00MFloat Cap1.830152wk Low--Dividend TTM2.51MShs Float719999.6400Historical High--Div YieldTTM6.10%Amplitude1.8300Historical Low2.3660Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Soligenix Stock Forum
🚀🚀🚀
Can this stock run like $Phio Pharmaceuticals (PHIO.US)$ and $Salarius Pharmaceuticals (SLRX.US)$ ?
EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'
Soligenix
Tells Benzinga HyBryte Expanded
Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'
Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
'Study Supported by $2.6 Million FDA Orphan Products Development...
EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Tells
Benzinga Co. Initiates Confirmatory
Phase III Trial Of HyBryte For The Treatment Ot Cutaneous T-Cell
Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Monday, 16th December at 7:30 am
FLASH2 Study opens patient enrollment
PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on devel...
No comment yet